Galapagos NV

(NASDAQ:GLPG)

Latest On Galapagos NV (GLPG):

Date/Time Type Description Signal Details
2023-05-06 09:51 ESTNewsGalapagos Stands Strong On Jyseleca Positive Clinical DataN/A
2023-05-05 21:26 ESTNewsGalapagos NV (GLPG) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 19:34 ESTNewsGalapagos GAAP EPS of €0.40, revenue of €178.9MN/A
2023-05-03 18:15 ESTNewsGalapagos Q1 2023 Earnings PreviewN/A
2023-05-03 05:16 ESTNewsGalapagos announces departure of COO and CFO Bart FiliusN/A
2023-03-30 21:01 ESTNewsGalapagos to transfer drug discovery and research activities in France to NovAliXN/A
2023-02-24 11:36 ESTNewsGalapagos NV (GLPG) Q4 2022 Earnings Call TranscriptN/A
2023-02-23 22:33 ESTNewsGalapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023N/A
2023-02-11 10:09 ESTNewsGalapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy RatingN/A
2023-02-09 18:47 ESTNewsGalapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's disease, cancels plan for EU filingN/A
2023-02-08 02:22 ESTNewsGalapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, BuyN/A
2022-12-31 07:11 ESTNewsGalapagos: Slow Transformation, But Led By An ExpertN/A
2022-11-07 11:28 ESTNewsGalapagos downgraded to market perform at Raymond James on unclear path forwardN/A
2022-11-03 19:29 ESTNewsGalapagos GAAP EPS of -€0.16, revenue of €410.2MN/A
2022-11-03 02:25 ESTNewsGalapagos Q3 2022 Earnings PreviewN/A
2022-10-10 20:03 ESTNewsGalapagos: Trading At Discount To Cash With A Fast-Growing Marketed ProductN/A
2022-10-03 19:25 ESTNewsEMA panel approves amending label for Galapagos' Jyseleca on testicular function effectsN/A
2022-09-09 14:41 ESTNewsGalapagos cut at Morgan Stanley on positive but slow transformationN/A
2022-08-06 18:23 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 20:20 ESTNewsGalapagos GAAP EPS of -€0.49, revenue of €274MN/A
2022-07-25 21:27 ESTNewsGalapagos stock dips after Jefferies slashes rating citing challenges aheadN/A
2022-06-21 19:06 ESTNewsGalapagos to enter cell therapy space with acquisition of CellPoint and AboundBioN/A
2022-05-30 23:31 ESTNewsMorgan Stanley updates biotechs with negative enterprise values & 2022 catalystsN/A
2022-05-25 07:04 ESTNewsGalapagos to license drug targets for inflammatory bowel disease from Scipher MedicineN/A
2022-05-20 09:10 ESTNewsGalapagos: Can The Company Turn Around?N/A
2022-05-06 13:39 ESTNewsGalapagos GAAP EPS of -€0.20, revenue of €136.3MN/A
2022-05-06 13:39 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 13:38 ESTNewsGalapagos NV 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-05 15:51 ESTNewsGalapagos Q1 2022 Earnings PreviewN/A
2022-03-28 07:24 ESTNewsGilead, Galapagos' Jyseleca gets approval in Japan for expanded use in ulcerative colitisN/A
2022-02-25 18:23 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-25 01:06 ESTNewsGalapagos GAAP EPS of -€1.58, revenue of €484.85MN/A
2022-02-24 05:28 ESTNewsGalapagos Q4 2021 Earnings PreviewN/A
2022-02-22 14:27 ESTNewsGalapagos: A History Of Disruptive FailuresN/A
2022-01-28 00:18 ESTNewsGalapagos at a six-month high after naming former J&J science chief as CEON/A
2022-01-27 07:39 ESTNewsGalapagos creates 1M subscription rights; stock rises 9%N/A
2022-01-26 14:26 ESTNewsEinhorn's Greenlight discloses positions in Global Payments, Capri, Galapagos, ODP Corp.N/A
2022-01-19 05:53 ESTNewsGalapagos' Jyseleca wins UK marketing authorization for ulcerative colitisN/A
2022-01-09 00:57 ESTNewsBiogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022N/A
2021-12-04 00:46 ESTNewsGalapagos announces increase in share capital with subscription right exercisesN/A
2021-12-02 09:17 ESTNewsGalapagos: The Investment Thesis Is More Appealing Than EverN/A
2021-11-15 16:53 ESTNewsGalapagos wins EU approval for Jyseleca for ulcerative colitisN/A
2021-11-08 23:33 ESTNewsGalapagos rises as analysts highlight a major catalyst aheadN/A
2021-11-05 17:29 ESTNewsGalapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 20:49 ESTNewsGalapagos reports Q3 resultsN/A
2021-11-03 23:37 ESTNewsGalapagos Q3 2021 Earnings PreviewN/A
2021-10-04 18:03 ESTNewsGalapagos posts results from post-hoc analyses of filgotinib in ulcerative colitisN/A
2021-09-22 14:07 ESTNewsGalapagos' filgotinib wins positive CHMP opinion for treatment of ulcerative colitisN/A
2021-08-19 18:51 ESTNewsGalapagos lowered to equal weight at Barclays; doubts acquisition driven upsideN/A
2021-08-08 04:48 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call TranscriptN/A

About Galapagos NV (GLPG):

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

GLPG Quotes by TradingView

See Advanced Chart

General

  • Name Galapagos NV
  • Symbol GLPG
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2005-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.glpg.com
View More

Valuation

  • Trailing PE 60.65
  • Price/Sales (Trailing 12 Mt.) 9.78
  • Price/Book (Most Recent Quarter) 1.69
  • Enterprise Value Revenue 1.18
  • Enterprise Value EBITDA 3.11
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$4.89
  • Next Year EPS Estimate -$4.50
  • Next Quarter EPS Estimate -$0.28
  • Profit Margin -58%
  • Return on Assets -2%
  • Return on Equity -11%
  • Earnings Per Share -$1.69
  • Revenue Per Share $0
  • Gross Profit 6.6 million
  • Quarterly Earnings Growth -77.6%
View More

Highlights

  • Market Capitalization 5.28 billion
  • Analyst Target Price $93.67
  • Book Value Per Share $25.49
View More

Share Statistics

  • Shares Outstanding 65.41 million
  • Shares Float 43.14 million
  • % Held by Insiders <1%
  • % Held by Institutions 11.77%
  • Shares Short 936943
  • Shares Short Prior Month 966729
  • Short Ratio 2.3
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 0.28
  • 52 Week High $233.14
  • 52 Week Low $79.59
  • 50 Day Moving Average 90.41
  • 200 Day Moving Average 114.01
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Galapagos NV (GLPG) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Galapagos NV (GLPG) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-18-$1.06-$1.5330.28%
2020-09-302020-11-05$131.82 million-$1.49-$0.99-51.08%
2020-06-302020-08-06$N/A-$2.10-$0.85-147.49%
2020-03-312020-05-07$N/A-$0.85-$0.862.01%
2019-12-312020-02-20$160.81 million-$2.34-$0.79-193.91%
2019-09-302019-10-24$701.86 million$7.05$3.29114.55%
2019-06-302019-07-25$76.28 million-$0.97-$1.2522.41%
2019-03-312019-04-25$45.88 million-$0.99-$1.022.59%
2018-12-312019-02-21$129.35 million$0.31-$0.90134.1%
2018-09-302018-10-24$119.48 million$0.32-$1.10129.08%
2018-06-302018-08-02$66.38 million-$0.49-$1.0051.42%
2018-03-312018-04-25$55.24 million-$0.89-$1.1119.74%
2017-12-312018-02-22$61.81 million-$0.73-$0.9120.04%
2017-09-302017-10-26$42.3 million-$0.84-$0.9310.37%
2017-06-302017-07-27$40.69 million-$0.86-$0.67-29.5%
2017-03-312017-04-27$42.65 million-$0.32-$0.5946.03%
2016-12-312017-02-23$86.89 million$1.05$0.10897.14%
2016-09-302016-10-27$19.3 million-$0.57-$0.6614.05%
2016-06-302016-07-28$36.92 million-$0.11-$0.2146.22%
2016-03-312016-04-28$16.88 million$0.89$1.30-31.2%
2015-12-312016-03-03$13.08 million-$1.69-$0.84-101.49%
2015-09-302015-11-13$11.52 million-$0.72$4.06-117.73%
2015-06-302015-08-06$19.68 million-$0.59-$0.35-68.57%

Galapagos NV (GLPG) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Galapagos NV (GLPG) Chart:

Galapagos NV (GLPG) News:

Below you will find a list of latest news for Galapagos NV (GLPG) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Galapagos NV (GLPG) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2012.50CALL0 0296.64TRUE00
2025-06-20150CALL0 0195.67TRUE00
2025-06-2017.50CALL0 0193.93TRUE00
2025-06-20200CALL0 0148.45TRUE00
2025-06-2022.56.2CALL0 22106.97TRUE00
2025-06-20250CALL0 070.79TRUE00
2025-06-2027.51.4CALL0 10829.08TRUE00
2025-06-20300.45CALL0 3259.66FALSE00
2025-06-2032.50CALL0 080.15FALSE00
2025-06-20350CALL0 0185.54FALSE00
2025-06-2012.50PUT0 0575.37FALSE00
2025-06-20150PUT0 0472.93FALSE00
2025-06-2017.50PUT0 0388.5FALSE00
2025-06-20200PUT0 0111.31FALSE00
2025-06-2022.50PUT0 081.41FALSE00
2025-06-20250PUT0 5188.69FALSE00
2025-06-2027.50.47PUT0 53126.96FALSE00
2025-06-20300PUT0 054.81TRUE00
2025-06-2032.50PUT0 0187.69TRUE00
2025-06-20350PUT0 0218.32TRUE00
2025-07-1812.50CALL0 094.19TRUE00
2025-07-18150CALL0 0123.85TRUE00
2025-07-1817.50CALL0 0201.18TRUE00
2025-07-18200CALL0 1079.92TRUE00
2025-07-1822.50CALL0 056.94TRUE00
2025-07-18250CALL0 38387.6TRUE00
2025-07-1827.52.2CALL0 1003534.26TRUE00
2025-07-18300.85CALL0 43248.05FALSE00
2025-07-1832.50.7CALL0 32111.17FALSE00
2025-07-18350.2CALL0 31128.58FALSE00
2025-07-1837.50.2CALL0 61143.61FALSE00
2025-07-18400CALL0 0156.9FALSE00
2025-07-1842.50CALL0 0168.82FALSE00
2025-07-1812.50PUT0 0324.92FALSE00
2025-07-18150PUT0 0267.21FALSE00
2025-07-1817.50PUT0 150289.94FALSE00
2025-07-18200PUT0 256.95FALSE00
2025-07-1822.50PUT0 153454.7FALSE00
2025-07-18250PUT0 16107.23FALSE00
2025-07-1827.50.75PUT17 151635.01FALSE-0.25-0.25
2025-07-18301.41PUT0 105544.45TRUE00
2025-07-1832.50PUT0 0107.42TRUE00
2025-07-18350PUT0 0124.93TRUE00
2025-07-1837.50PUT0 0140.1TRUE00
2025-07-18400PUT0 0153.53TRUE00
2025-07-1842.50PUT0 0165.6TRUE00
2025-10-1712.50CALL0 080.73TRUE00
2025-10-17150CALL0 068.96TRUE00
2025-10-1717.50CALL0 055.06TRUE00
2025-10-17200CALL0 030.53TRUE00
2025-10-1722.50CALL0 029.43TRUE00
2025-10-17254.1CALL0 3454.63TRUE00
2025-10-1727.50CALL0 233.53TRUE00
2025-10-17302.2CALL0 1847.77FALSE00
2025-10-1732.50CALL0 661.17FALSE00
2025-10-17351CALL62 245.04FALSE10
2025-10-1737.50CALL0 077.9FALSE00
2025-10-17400CALL0 086.17FALSE00
2025-10-1712.50PUT0 0182.89FALSE00
2025-10-17150PUT0 0150.66FALSE00
2025-10-1717.50PUT0 0124.13FALSE00
2025-10-17200PUT0 2101.26FALSE00
2025-10-1722.50PUT0 180.77FALSE00
2025-10-17250PUT0 4161.6FALSE00
2025-10-1727.52.05PUT0 6147.12FALSE00
2025-10-17300PUT0 434.66TRUE00
2025-10-1732.50PUT0 035.76TRUE00
2025-10-17350PUT0 033.72TRUE00
2025-10-1737.50PUT0 038.63TRUE00
2025-10-17400PUT0 048.59TRUE00
2026-01-1612.50CALL0 0140.94TRUE00
2026-01-16150CALL0 0114.83TRUE00
2026-01-1617.50CALL0 033.29TRUE00
2026-01-16200CALL0 075.25TRUE00
2026-01-1622.50CALL0 028.01TRUE00
2026-01-16250CALL0 025.85TRUE00
2026-01-1627.50CALL0 026.5TRUE00
2026-01-16300CALL0 036.65FALSE00
2026-01-1632.50CALL0 045.97FALSE00
2026-01-16350CALL0 053.04FALSE00
2026-01-1637.50CALL0 060.54FALSE00
2026-01-16400CALL0 065.42FALSE00
2026-01-1612.50PUT0 0141.95FALSE00
2026-01-16150PUT0 0117.1FALSE00
2026-01-1617.50PUT0 096.67FALSE00
2026-01-16200PUT0 079.08FALSE00
2026-01-1622.50PUT0 063.32FALSE00
2026-01-16250PUT0 049.28FALSE00
2026-01-1627.50PUT0 035.82FALSE00
2026-01-16300PUT0 034.25TRUE00
2026-01-1632.50PUT0 028.85TRUE00
2026-01-16350PUT0 032.65TRUE00
2026-01-1637.50PUT0 035.47TRUE00
2026-01-16400PUT0 037.71TRUE00

Latest GLPG Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$54.06
Jun 13, 2022 7:58 PM EST10$53.98
Jun 13, 2022 7:58 PM EST1$53.98
Jun 13, 2022 7:59 PM EST1$53.985
Jun 13, 2022 7:59 PM EST100$53.99

Galapagos NV (GLPG) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000090221920000071/0000902219-20-000071-index.htm
2019-07-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465919040709/0001104659-19-040709-index.htm
2019-07-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919041473/0001104659-19-041473-index.htm
2019-08-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919047927/0001104659-19-047927-index.htm
2019-11-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919059005/0001104659-19-059005-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465920021860/0001104659-20-021860-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000114036120003311/0001140361-20-003311-index.htm
2019-05-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003728/0001171843-19-003728-index.htm
2019-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003920/0001171843-19-003920-index.htm
2019-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004030/0001171843-19-004030-index.htm
2019-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004093/0001171843-19-004093-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004317/0001171843-19-004317-index.htm
2019-07-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004585/0001171843-19-004585-index.htm
2019-07-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004659/0001171843-19-004659-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005832/0001171843-19-005832-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005833/0001171843-19-005833-index.htm
2019-09-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006023/0001171843-19-006023-index.htm
2019-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006051/0001171843-19-006051-index.htm
2019-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006114/0001171843-19-006114-index.htm
2019-10-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006401/0001171843-19-006401-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006466/0001171843-19-006466-index.htm
2019-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006850/0001171843-19-006850-index.htm
2019-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006892/0001171843-19-006892-index.htm
2019-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007092/0001171843-19-007092-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007260/0001171843-19-007260-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007410/0001171843-19-007410-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007516/0001171843-19-007516-index.htm
2019-11-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007642/0001171843-19-007642-index.htm
2019-11-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007826/0001171843-19-007826-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008012/0001171843-19-008012-index.htm
2019-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008255/0001171843-19-008255-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000139/0001171843-20-000139-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000140/0001171843-20-000140-index.htm
2020-01-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000174/0001171843-20-000174-index.htm
2020-01-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000237/0001171843-20-000237-index.htm
2020-01-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000469/0001171843-20-000469-index.htm
2020-01-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000556/0001171843-20-000556-index.htm
2020-03-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320001794/0001171843-20-001794-index.htm
2020-04-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002640/0001171843-20-002640-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002674/0001171843-20-002674-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002689/0001171843-20-002689-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320003977/0001171843-20-003977-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004053/0001171843-20-004053-index.htm
2020-06-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004164/0001171843-20-004164-index.htm
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-07-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005194/0001171843-20-005194-index.htm
2020-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005906/0001171843-20-005906-index.htm
2020-08-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005998/0001171843-20-005998-index.htm
2020-08-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006087/0001171843-20-006087-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006405/0001171843-20-006405-index.htm
2020-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006525/0001171843-20-006525-index.htm
2020-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006651/0001171843-20-006651-index.htm
2020-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006681/0001171843-20-006681-index.htm
2020-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006727/0001171843-20-006727-index.htm
2020-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007002/0001171843-20-007002-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007061/0001171843-20-007061-index.htm
2020-10-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007261/0001171843-20-007261-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007481/0001171843-20-007481-index.htm
2020-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007726/0001171843-20-007726-index.htm
2019-08-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519234109/0001193125-19-234109-index.htm
2019-09-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519250691/0001193125-19-250691-index.htm
2019-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519272244/0001193125-19-272244-index.htm
2019-10-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519274853/0001193125-19-274853-index.htm
2020-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520088879/0001193125-20-088879-index.htm
2020-04-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520126328/0001193125-20-126328-index.htm
2020-05-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520139028/0001193125-20-139028-index.htm
2020-10-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1421876/000119312520267249/0001193125-20-267249-index.htm
2019-07-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837019006344/0001558370-19-006344-index.htm
2020-03-2720-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1421876/000155837020003270/0001558370-20-003270-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837020009632/0001558370-20-009632-index.htm